ArticleCancer discovery2022
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.
Abstract read
In one paragraph
Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular Tumor Boards clinical impact on patient care and structural features: A systematic review and meta-analysis.PLoS medicine · 2026Pooled it
- Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Trial
- Ex Vivo Microtumor Testing to Predict Chemotherapy Responses in Patients with Bladder Cancer.European urology open science · 2026Article
- Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.Leukemia · 2026Article
- Article
- Decoding the actionable potential of ribosome biogenesis in acute myeloid leukemia.Haematologica · 2026Article
- Article
- Article
- The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia.British journal of haematology · 2026Article
- Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia.British journal of haematology · 2026Article
- Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies.NPJ precision oncology · 2026Article
- NAMPT haploinsufficiency is a therapeutic vulnerability to NAMPT inhibition in -7/-7q MDS.Biomarker research · 2026Article
- Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction.Communications medicine · 2026Article
- A multi-center study on the consistency of drug sensitivity testing in patients with acute myeloid leukemia.NPJ precision oncology · 2026Article
- Functional drug screening of tumor organoids on an active-matrix digital microfluidic chip for cancer precision medicine.Microsystems & nanoengineering · 2026Article
- An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia.Communications medicine · 2026Article
- Solubility based mechanistic profiling of combinatorial drug therapy.Nature communications · 2026Article
- Midostaurin response in AML is shaped by a progenitor-like cell state selectively targeted by SMAC mimetics.NPJ precision oncology · 2026Article
- Landscape of circular RNAs in acute myeloid leukemia and their clinical significance.NPJ precision oncology · 2026Article
68 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors.
Disha MalaniInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
Ashwini KumarInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
Oscar BrückHematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland.
Mika KontroInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-6353-0664
Bhagwan YadavInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-3502-9335
Monica HellesøyDepartment of Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway.ORCID 0000-0002-0115-7427
Heikki KuusanmäkiInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
Olli DufvaHematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland.
Matti KankainenInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
Samuli EldforsInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-5056-4750
Swapnil PotdarInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-2778-6918
Jani SaarelaInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-7306-7175
Laura TurunenInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-0274-4794
Alun ParsonsInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
Imre VästrikInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-6658-9311
Katja KivinenInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
Janna SaarelaInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-0853-6219
Riikka RätyHematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland.
Minna LehtoHematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland.
Maija WolfInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
Bjorn Tore GjertsenDepartment of Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway.
Satu MustjokiHematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland.ORCID 0000-0002-0816-8241
Tero Aittokallio *Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-0886-9769
Krister Wennerberg *Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-1352-4220
Caroline A Heckman *Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-4324-8706
Olli Kallioniemi *Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland. kimmo.porkka@helsinki.fi olli.kallioniemi@scilifelab.se.
Kimmo Porkka *Hematology Research Unit Helsinki, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland. kimmo.porkka@helsinki.fi olli.kallioniemi@scilifelab.se.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We generated
Indexed as
Decision Support TechniquesPatient Care TeamPrecision MedicineFemaleFinlandHumansLeukemia, Myeloid, AcuteMaleMiddle AgedRemission InductionSurvival Analysis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.